EDLS-302

About Edulis Therapeutics

Edulis Therapeutics is an early-stage biotechnology company pioneering a novel endoscopic drug delivery platform for gastrointestinal medicine. Its lead program targets inflammatory bowel disease (IBD), with a pipeline exploring applications in microbiome modulation and weight loss. The company's value proposition centers on improving patient quality of life through a long-acting, localized delivery system that aims to enhance drug bioavailability, reduce systemic side effects, and lower overall treatment costs. Backed by grant funding and competition accolades, Edulis is developing both the therapeutic implants and the associated endoscopic insertion tool as an integrated platform.

Therapeutic Areas

Other Microbiome Modulation Drugs